FDA Releases Draft Guidance for Industry on Cover Letter Attachments for Controlled Correspondences and Abbreviated New Drug Application Submissions

Summary

The Food and Drug Administration (FDA) has made available a draft guidance document to help applicants and holders of abbreviated new drug applications (ANDAs) prepare cover letter attachments for submissions to the Office of Generic Drugs (OGD) and other FDA-regulated documents.